Drug Profile


Alternative Names: p55TNFR-Ig; RO 452081; Tenefuse; TNFr IgG1; TNFR55 IgG1

Latest Information Update: 08 Apr 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Genentech; Roche
  • Class Anti-inflammatories; Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic asthma; Rheumatoid arthritis; Septic shock

Most Recent Events

  • 31 Dec 2002 Discontinued - Preclinical for Allergic asthma in USA (unspecified route)
  • 11 Jul 2000 A study has been added to the pharmacokinetics section
  • 20 Sep 1999 Discontinued-III for Septic shock in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top